JAC Advance Access published online on March 13, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl092
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Present address. Stanford University Medical Center
* To whom correspondence should be addressed. Many patients on highly active antiretroviral therapy (HAART) who achieve undetectable HIV-1 RNA levels experience transient episodes of detectable viraemia or blips, suggesting there is incomplete suppression of viral replication. This raises concern that drug resistance mutations could develop and cause eventual treatment failure. However, data from recent studies indicate that most blips are actually random biological and statistical variations around a mean viral load below detectable levels (<50 copies/mL) or due to false elevations of viral load from laboratory processing artefacts. Blips are not typically associated with the development of resistance mutations and most importantly are not associated with virological or clinical failure of previously adequate HAART.
Commissioned leading article
HIV-1 viral load blips are of limited clinical significance
Patricia K. Lee 1,
Tara L. Kieffer 2,
Robert F. Siliciano 3,
and
Richard E. Nettles 4 *
2 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Present address. Vertex Pharmaceuticals
3 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Howard Hughes Medical Institute, Baltimore, MD, USA
4 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Richard E. Nettles, E-mail: Richard.Nettles{at}BMS.com
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S M Casserly, G R Scott, and M MacDougall General practitioner involvement and patient outcomes in HIV management Int J STD AIDS, July 1, 2009; 20(7): 503 - 505. [Abstract] [Full Text] [PDF] |
||||
![]() |
M R Jordan, H La, H D Nguyen, H Sheehan, T T M Lien, D V Duong, J Hellinger, C Wanke, and A M Tang Correlates of HIV-1 viral suppression in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam Int J STD AIDS, June 1, 2009; 20(6): 418 - 422. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Garcia-Gasco, I. Maida, F. Blanco, P. Barreiro, L. Martin-Carbonero, E. Vispo, J. Gonzalez-Lahoz, and V. Soriano Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome J. Antimicrob. Chemother., March 1, 2008; 61(3): 699 - 704. [Abstract] [Full Text] [PDF] |
||||

